In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NitroMed, Inc.

Latest From NitroMed, Inc.

Generics And Biosimilars Industry Reshaped By Transformations

The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.

Outlook 2023 Generic Drugs

Pandemic Drives China Surge In Asia 100 Sales

Notable new entrants moved into the Asia 100 this year, with growth catalyzed by COVID-19 vaccines.

Outlook 2023 Companies

Finance Watch: No New IPOs, But Two Firms Take The SPAC Route

Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.

Financing Business Strategies

Big Pharma Restructures Commercial Teams In India

More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.

India Commercial
See All

Company Information

UsernamePublicRestriction

Register